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Mechanistic understanding of antibiotic action can yield crucial insights that aid in the design of 
new antibiotics. In this issue, Mukhopadhyay et al. (2008) uncover the mechanism by which the 
antibiotic myxopyronin inhibits bacterial RNA polymerase, suggesting a new target region in RNA 
polymerase for inhibitor design.Given the implications for human health, 
the development of antibiotic resistance 
in pathogenic bacteria is a topic of more 
than academic interest. The emergence 
of bacterial strains resistant to rifamy-
cins, a group of antibiotics that inhibit 
the bacterial RNA polymerase (RNAP), 
has greatly compromised the treatment 
of tuberculosis. Rifamycins are the only 
antibiotics in widespread use to treat 
tuberculosis (Shinnick, 1996), a disease 
that is estimated by the World Health 
Organization to have killed 1.7 million people in 2006 alone. Thus, there is an 
urgent need to develop new antibiotics 
to treat infections caused by rifamy-
cin- or multidrug-resistant bacteria. The 
bacterial RNAP is an attractive target 
for development of such drugs (Chopra, 
2007). As a large multisubunit enzyme, 
RNAP is expected to have multiple sites 
that could be bound by small mole-
cules. Also, although the transcriptional 
machinery of prokaryotes and eukary-
otes exhibits similarities in structure and 
mechanism, there has been sufficient Cell 135divergence in even the most conserved 
RNAP subunits to make specific target-
ing of bacterial or eukaryotic RNAPs 
possible. Indeed, several antibiotics 
that specifically inhibit bacterial RNAP 
or eukaryotic RNAP II have been found 
to occur naturally; rifamycins are one 
such example (Campbell et al., 2001). 
It seems wise then to begin with what 
nature has developed in our search for 
improved antibiotic compounds. This is 
the approach taken by Mukhopadhyay 
et al. (2008) in their study, in this issue of Figure 1. Initiation of RNA Polymerase Transcription and Its Inhibition by Myxopyronin
RNA polymerase (RNAP) can exist in closed (A; PDB 1I6H, Gnatt et al., 2001) and open (B; PDB 1I3Q, Cramer et al., 2000) conformations. RNAP converts 
between open and closed confirmations by the 30° rotation of the clamp domain (cyan) around the switch region located at the base of the clamp. The clamp 
domain is formed by part of the largest RNAP subunit (β' in bacterial RNAP; RPB1 in eukayotic RNAP II). Clamp opening is required to allow DNA to bind in the 
catalytic cleft (C) and is followed by clamp closure (D; PDB 2VUM, Brueckner and Cramer, 2008) in a step coupled to promoter melting to allow transcription 
initiation. The antibiotic myxopyronin (myx) binds in the switch (E; PDB 3DXJ, Mukhopadhyay et al., 2008) and blocks clamp opening to prevent DNA binding., October 17, 2008 ©2008 Elsevier Inc. 205
Cell, describing the mechanism of bac-
terial RNAP inhibition by the α-pyrone 
antibiotic myxopyronin (myx), which is 
produced by the bacteria Myxococcus 
fulvus (Irschik et al., 1983).
RNAP resembles a crab claw (Fig-
ure 1A) that must open to allow DNA to 
bind in the catalytic cleft. It does so via 
a swinging motion of one of the “pin-
cers” (the clamp) that is formed by part 
of the largest RNAP subunit (β′ in bac-
terial RNAP; RPB1 in eukayotic RNAP 
II) (Figures 1B and 1C). Following DNA 
binding, the clamp swings back to close 
over the DNA (Figure 1D) in a step that 
appears coupled to promoter melting 
during transcription initiation. This step 
is also likely to be required for transcrip-
tion complex stability and processivity 
during transcription elongation. To study 
how RNAP is inhibited by myx, Mukho-
padhyay et al. needed to find the myx-
binding site. A screen for myx resistance 
in the bacteria Escherichia coli uncov-
ered mutations in three RNAP residues 
in the switch region that forms the hinge 
around which the clamp rotates to open 
and close the DNA-binding cleft. The 
authors then performed targeted muta-
genesis of the RNAP switch region in 
E. coli to identify residues that, when 
mutated, confer myx resistance. In the 
125 myx-resistant E. coli strains they 
identified, the authors found 13 residues 
within the switch region whose individual 
mutation conferred resistance to myx. 
Remarkably, all 13 of these residues are 
conserved in the RNAPs of different bac-
teria, thus explaining myx’s broad spec-
trum activity against both Gram-positive 
and Gram-negative pathogens. Further-
more, consistent with myx’s bacteria-
specific inhibitory activity, 3 of these 13 
residues are not conserved in eukaryotic 
RNAPs.
Binding experiments showed that 
mutations in any of these 13 residues dis-
rupted myx binding, thus implicating the 
switch region as the site of myx binding. 
Mukhopadhyay and colleagues confirmed 
this mode of myx binding by determining 
the structure of RNAP from the bacteria 
Thermus thermophilus in a complex with 
myx. The structure revealed that myx is 
almost completely buried in a hydropho-
bic pocket within the switch, far from the 
catalytic center (Figure 1E). This sug-
gested that myx functions allosterically 206 Cell 135, October 17, 2008 ©2008 Elsevby inhibiting either the opening or closing 
of the clamp. But was myx jamming the 
clamp’s hinge to prevent clamp opening 
and DNA binding, or was it binding to the 
opened clamp to prevent clamp closure 
after DNA has bound? Although the crys-
tal structure implied the former scenario, it 
was possible that this aspect of the struc-
ture was misleading given that crystal 
packing can alter protein conformations 
from their state in solution. To distinguish 
between these two possibilities, Mukho-
padhyay et al. characterized the effects of 
myx on RNAP promoter binding in vitro. 
They found that myx inhibited promoter 
binding only if it was added to the in vitro 
reaction containing RNAP before the pro-
moter DNA was added. If myx was added 
after the promoter DNA was introduced 
into the reaction, no binding inhibition 
was observed. Moreover, myx had similar 
inhibitory effects on both abortive (short) 
and runoff (long) transcript synthesis in 
vitro, consistent with myx inhibiting DNA 
binding rather than affecting transcription 
complex stability or processivity follow-
ing DNA binding. Furthermore, myx did 
not inhibit RNAP binding to promoters 
that lacked the DNA duplex region usually 
bound within the RNAP “claw” and melted 
during transcription initiation, implying 
that myx locks the clamp in a closed or 
partially closed state that still allows the 
RNAP to accommodate a single strand of 
DNA but not a duplex.
This characterization of the mecha-
nism of RNAP inhibition by myx has fur-
ther implications for the mode of action of 
two other antibiotics, corallopyronin and 
ripostatin. Mukhopadhyay et al. showed 
that both of these antibiotics have identical 
patterns of inhibition and order-of-addition 
effects in promoter-binding experiments. 
Thus, it is likely that these antibiotics have 
a mechanism akin to myx—binding in the 
RNAP switch region to block clamp open-
ing and promoter binding. Indeed, almost 
without exception, mutant E. coli resistant 
to any one of these three antibiotics are 
also resistant to the other two. This is par-
ticularly surprising for ripostatin, a macro-
cylic-lactone molecule that, unlike coral-
lopyronin, is similar to myx only in terms of 
size and general hydrophobicity.
Other compounds inhibit RNAP by 
interfering with conformational changes. 
For example, streptolydigin binds to 
bacterial RNAP near the base of the pin-ier Inc.cer opposite the clamp and is believed to 
function by inhibiting the conformational 
changes required to organize the RNAP 
catalytic center or to translocate the 
RNAP during each cycle of nucleotide 
addition (Tuske et al., 2005). The toxin 
of the death cap mushroom, α-amanitin, 
binds to eukaryotic RNAP II in a region 
near the streptolydigin-binding site and 
has been proposed to work via a simi-
lar mechanism (Kaplan et al., 2008). 
Why might sites of focused conforma-
tional change be preferentially targeted 
by these naturally occurring inhibitors? 
Most obviously, jamming the mov-
ing parts of the transcription machine, 
like jamming the moving parts of any 
machine, is an effective way to stop it in 
its tracks. But there may be other fea-
tures of these sites that make them ready 
targets for small-molecule inhibitors. As 
points of articulation between different 
RNAP domains or subdomains, these 
sites may be like the chinks in a suit of 
armor—weak points where a sword can 
be driven in. Indeed, myx is bound in 
the switch region in a manner that sug-
gests it has wormed its way into this site, 
a mechanism that would require RNAP 
flexing to allow myx binding. This study 
is the latest chapter in a two decade long 
effort to understand RNAP structure and 
mechanism. With the myx-RNAP struc-
ture in hand, Mukhopadhyay et al. can 
now propose rational modifications that 
should enhance myx affinity and effec-
tiveness in RNAP inhibition. This next 
step can only be contemplated because 
of the advance in understanding of myx 
mechanism achieved through a compre-
hensive approach that brought together 
genetics, biochemistry, and crystallog-
raphy. Mechanistic understanding is the 
prerequisite to manipulating what nature 
has provided. To paraphrase Al Pacino 
in the film Scarface, when you get the 
knowledge, then you get the power.
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mRNA transcripts. In their study linking 
THO with the NPC, Rougemaille et al. 
now add to this understanding of the 
consequence of losing THO function.
Using a modified method of fraction-
ating chromatin, Rougemaille and col-
leagues now establish a connection 
between mRNA packaging and the NPC. 
This work also highlights the potential 
biases inherent in analyzing chroma-
tin with techniques such as chromatin 
immunoprecipitation (ChIP). The authors 
observed that heat shock genes in S. 
cerevisiae display an aberrant chromatin 
conformation in strains harboring muta-
tions in the THO complex (tho strains) 
or in the THO-associated RNA helicase 
Sub2. Perplexingly, regular chromatin 
preparation techniques for ChIP, which 
include a centrifugation step at 18,000 g 
to remove cellular debris from the chro-
matin fraction, resulted in the loss of DNA 
from the 3′ regions of these heat shock 
genes. Interestingly, if the centrifugation 
step was performed at a lower speed of 
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